Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

CVS Health Gains as Recent Medicare, Contract, and Analyst Updates Support Sentiment

None

CVS Health (CVS) is up 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a mix of improving sentiment rather than a single major headline. Investors may be responding to recent signs that CVS’s Medicare Advantage business is entering the important annual enrollment season on steadier footing, along with supportive analyst commentary and a newly disclosed supply-chain contract extension.

Details:

  • CVS recently scheduled its third-quarter 2026 earnings call for November 4, which can draw attention to companies heading into a key reporting period.
  • Aetna, the company’s insurance arm, introduced its 2027 Medicare plan lineup in early October, highlighting affordability and benefit design as the market focuses on Medicare Advantage positioning for next year.
  • Cardinal Health disclosed a binding letter of intent to extend its pharmaceutical distribution agreements with CVS through June 2032, suggesting continuity in an important operating relationship.
  • Recent analyst notes have stayed broadly constructive on CVS, including a higher target from one firm earlier this week and continued buy-equivalent ratings despite some target adjustments.
  • Sources:

    CVS Health, SEC, Stock Analysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $CVS Insider Trading Activity

    CVS Insider Trades

    $CVS insiders have traded $CVS stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

    Here’s a breakdown of recent trading of $CVS stock by insiders over the last 6 months:

    • LARRY ROBBINS has made 0 purchases and 7 sales selling 3,372,000 shares for an estimated $317,471,136.

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS
    Receive CVS Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $CVS Hedge Fund Activity

    We have seen 1,057 institutional investors add shares of $CVS stock to their portfolio, and 819 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $CVS Price Targets

    Multiple analysts have issued price targets for $CVS recently. We have seen 14 analysts offer price targets for $CVS in the last 6 months, with a median target of $109.0.

    Here are some recent targets:

    • Ben Hendrix from RBC Capital set a target price of $113.0 on 07/09/2026
    • Sarah James from Cantor Fitzgerald set a target price of $110.0 on 07/07/2026
    • Allen Lutz from B of A Securities set a target price of $110.0 on 06/23/2026
    • Ann Hynes from Mizuho set a target price of $115.0 on 06/08/2026
    • Erin Wright from Morgan Stanley set a target price of $111.0 on 06/04/2026
    • David Macdonald from Truist Securities set a target price of $108.0 on 06/01/2026
    • Andrew Mok from Barclays set a target price of $106.0 on 05/26/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles